See "Focused therapies in CLL: mechanisms of resistance and methods for administration" on webpage 471. . intolerance). Ibrutinib is The present gold normal therapy for clients with relapsed/refractory disorder, determined by the outcomes of various phase I-III trials, 115–119 but This can be also switching for two principal good reasons: https://elizabethc221umd1.celticwiki.com/user